Applications

1532 – Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item

Service or technology in this application

Molecular testing for the diagnosis of polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) can establish the presence or absence of specific mutations known to occur in patients with these disorders. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) gene testing in patients with PV or ET. The proposed medical service being requested is the expansion of MBS item 73325 to allow testing for calreticulin (CALR) mutations in patients with PV or ET, and testing for JAK2, MPL and CALR genes in patients with primary myelofibrosis (PMF).

Type: Investigative

Medical condition this application addresses

Myeloproliferative neoplasms (MPNs) are a group of disorders in which bone marrow stem cells grow and reproduce abnormally. PV, ET and PMF are MPN's.

Previous applications

1125 – Molecular Testing for the Diagnosis of Myeloproliferative Disorders

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 
    • 8 February 2019
    • 8 to 9 October 2020
  • MSAC meeting: 
    • 28 to 29 March 2019
    • 26 to 27 November 2020